AbbVie (ABBV): The $11B immunology bridge past Humira [Q2 2026]

AbbVie’s Q2 2026 results prove there is lucrative life after a mega-blockbuster patent cliff, leveraging surging immunology assets to fund their next decade of pipeline growth.In ~10 minutes:• Skyrizi and Rinvoq surging over 24% to offset the legacy Humira loss.• How the Inflation Reduction Act drove a 29% decline for oncology drug Imbruvica.• Launching a short-acting "preview" cosmetic toxin to lower patient friction.• Financing an $11B Apogee acquisition to secure their 2030s pipeline.Even with a top-line and bottom-line beat, shares gapped down over the immediate financing costs and EPS dilution tied to the massive Apogee M&A deal. But beneath the short-term balance sheet noise, management is successfully pulling off one of the toughest transitions in pharmaceutical history. 🧬Company: AbbVie Inc. (ABBV) | Q2 FY2026AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.